Effective Date: 2/27/2024

End Date: 11/20/2024

CBD & Opioid Use Research Study

Researchers at the Icahn School of Medicine at Mount Sinai are conducting a study in adults who are using methadone or buprenorphine as a treatment for opioid use to find out whether cannabidiol (CBD) can assist treatment.

Fast Facts

Current or Past Opioid Use Disorder

Using Methadone or Buprenorphine

Compensation Provided

Conducted in NYC

Study Background

Can CBD help the treatment of individuals with opioid use disorder?

Cannabidiol (CBD) is a chemical compound found in cannabis. Unlike THC, it is non-addictive and does not cause a “high”. In this research study, we want to find out whether people who are already using an opioid agonist therapy, such as methadone or buprenorphine, could benefit from adding treatment with CBD.

Eventually, the findings of this study might be useful for treating opioid use disorder and improving people’s process of recovery.

Study Background

Can CBD help reduce craving and anxiety in individuals with opioid use disorder?

Cannabidiol (CBD) is a chemical compound found in cannabis. Unlike THC, it is non-addictive and does not cause a “high”. In this research study, we want to find out whether people who are already using an opioid agonist therapy, such as methadone or buprenorphine, could benefit from adding treatment with CBD.

Eventually, the findings of this study might be useful for treating opioid use disorder and improving people’s process of recovery.

Additional Information

In this research study, we are trying to understand how CBD affects individuals with opioid use disorder who are currently being treated with methadone or buprenorphine. We hope that adding treatment with CBD will help to prevent relapse.

During the study, you will continue your current treatment with methadone or buprenorphine and may be asked to take cannabidiol (CBD) that will be provided by the study team. You will also need to come to the Icahn School of Medicine at Mount Sinai for multiple study visits.

As a participant, compensation will be provided.

There is no cost for you to participate in our research study.

IRB # 21-00607, PI: Yasmin Hurd, PhD

IRB # 21-00607, PI: Yasmin Hurd, PhD